Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999051 | 0.95 | ALDH1A1 (0.41) | MAPTALDH1A1LMNAGAATP53 | |
| SCHEMBL20999053 | 0.93 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAGAATP53 | |
| SCHEMBL22668975 | 0.92 | MAPT (0.46) | MAPTALDH1A1LMNA | |
| SCHEMBL22669230 | 0.89 | HTT (0.39) | GAATP53ALOX12 | |
| SCHEMBL20999208 | 0.88 | ATF4 (0.44) | MAPT | |
| SCHEMBL20999620 | 0.85 | ATF4 (0.50) | MAPTALDH1A1LMNAGAATP53 | |
| SCHEMBL22669127 | 0.85 | ATF4 (0.48) | MAPTALDH1A1LMNAGAATP53 | |
| SCHEMBL19569273 | 0.84 | ATF4 (0.44) | MAPTALDH1A1LMNAGAATP53 | |
| SCHEMBL22669484 | 0.84 | HTT (0.40) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL20973901 | 0.81 | ATF4 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MAPT 3293/4885ALDH1A1 3433/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.